Xvivo Perfusion Q1: Falls short of high expectations

Research Note

2017-04-25

11:13

Total sales in Q1 failed to meet our expectations, but sales related to warm perfusion (excl. durable goods) continued to witness strong growth. The gross margin came in higher than expected, but higher operating expenses than anticipated resulted in an EBIT lower than our forecast. We have a neutral view of the report, but keep our positive view of the company’s future growth potential.

AN

Arvid Necander

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.